-+ 0.00%
-+ 0.00%
-+ 0.00%

Mizuho Maintains Outperform on Enliven Therapeutics, Raises Price Target to $73

Benzinga·08/18/2026 11:48:29
Listen to the news
Mizuho analyst Salim Syed maintains Enliven Therapeutics (NASDAQ:ELVN) with a Outperform and raises the price target from $62 to $73.